PharmaSGP Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Natalie Weigand

Chief executive officer

€865.0k

Total compensation

CEO salary percentage	34.7%
CEO tenure	4.2yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.2yrs

Recent management updates

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

CEO Compensation Analysis

How has Natalie Weigand's remuneration changed compared to PharmaSGP Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€865k	€300k	€16m
Sep 30 2023	n/a	n/a	€15m
Jun 30 2023	n/a	n/a	€14m
Mar 31 2023	n/a	n/a	€13m
Dec 31 2022	€314k	€250k	€12m
Sep 30 2022	n/a	n/a	€11m
Jun 30 2022	n/a	n/a	€11m
Mar 31 2022	n/a	n/a	€11m
Dec 31 2021	€272k	€250k	€11m
Sep 30 2021	n/a	n/a	€8m
Jun 30 2021	n/a	n/a	€8m
Mar 31 2021	n/a	n/a	€9m
Dec 31 2020	€279k	€258k	€11m
Sep 30 2020	n/a	n/a	€16m
Jun 30 2020	n/a	n/a	€17m
Mar 31 2020	n/a	n/a	€17m
Dec 31 2019	€141k	€141k	€17m

Compensation vs Market: Natalie's total compensation ($USD931.91K) is above average for companies of similar size in the German market ($USD713.28K).

Compensation vs Earnings: Natalie's compensation has increased by more than 20% in the past year.

CEO

Natalie Weigand (42 yo)

4.2yrs

Tenure

€865,000

Compensation

Ms. Natalie Weigand serves as the Chief Executive Officer at PharmaSGP Holding SE since June 2020 and also serves as a Member of Management Board since March 04, 2020. She joined the FUTRUE Group as the le...

Board Members

Name	Position	Tenure	Compensation	Ownership
Axel Rebien	Member of the Supervisory Board	3.9yrs	€50.00k	no data
Madlena Hohlefelder	Deputy Chairwoman of the Supervisory Board	4.2yrs	no data	48.95% € 133.8m
Clemens Fischer	Chairman of the Supervisory Board	4.2yrs	no data	no data

4.2yrs

Average Tenure

48yo

Average Age

Experienced Board: PSG's board of directors are considered experienced (4.2 years average tenure).

PharmaSGP Holding Management

Management criteria checks 1/4

Key information

Recent management updates

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age